Autopsy report · NCT02361346

Safety, PD & Efficacy of MT-3724 for the Treatment of Patients With Relapsed or Refractory DLBCL

“Sponsor decision following clinical hold”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 6 years 1 month before it stopped.
• 38 participants enrolled.
• Results were posted on the registry 1 year 5 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 1, Phase 2

Sponsor

Molecular Templates, Inc.

Sponsor type

Industry

Conditions

Non-Hodgkin's B-cell Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell; Small Lymphocytic Leukemia; Diffuse Large B Cell Lymphoma; Blood Cancer; Hematological Malignancy

Interventions

MT-3724 Phase 1; MT-3724 Phase 2

Participants

38

Sites

41

Countries

Belarus, Canada, Georgia, Israel, Moldova, Poland, Serbia, Spain, Ukraine, United States

Trials that died the same way

• Utility of Remote Lung Auscultation in Transitions of Care After Pulmonary Exacerbations of COPD
  “Sponsor Hold” (79% match in meaning)
• Pacritinib Combined With Decitabine or Cytarabine in Older Patients With AML
  “The study was put on clinical hold by the sponsor since Feb 9th 2016, and was later decided not to re-open due to financial constraints.” (75% match in meaning)
• GB5121 in Adult Patients With Relapsed/Refractory CNS Lymphoma
  “Sponsor decision” (70% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.